1. Home
  2. PDFS vs CAPR Comparison

PDFS vs CAPR Comparison

Compare PDFS & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PDF Solutions Inc.

PDFS

PDF Solutions Inc.

HOLD

Current Price

$33.67

Market Cap

1.3B

Sector

Technology

ML Signal

HOLD

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

HOLD

Current Price

$30.62

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PDFS
CAPR
Founded
1992
2005
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.3B
IPO Year
2000
2011

Fundamental Metrics

Financial Performance
Metric
PDFS
CAPR
Price
$33.67
$30.62
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
8
Target Price
$33.67
$44.63
AVG Volume (30 Days)
254.7K
1.2M
Earning Date
05-07-2026
03-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$22.13
N/A
Revenue Next Year
$18.92
$31.86
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.91
$4.30
52 Week High
$36.99
$40.37

Technical Indicators

Market Signals
Indicator
PDFS
CAPR
Relative Strength Index (RSI) 54.66 58.59
Support Level $30.72 $25.33
Resistance Level $34.97 $36.49
Average True Range (ATR) 1.40 2.03
MACD -0.01 0.12
Stochastic Oscillator 78.27 49.96

Price Performance

Historical Comparison
PDFS
CAPR

About PDFS PDF Solutions Inc.

PDF Solutions Inc provides products and services designed to empower organizations across the semiconductor and electronics ecosystem to connect, collect, manage, and analyze data about design, equipment, manufacturing, and test to improve the yield and quality of their products and operational efficiency. The Company's products, services, and solutions include proprietary software, physical intellectual property (IP) for integrated circuit (IC) designs, electrical measurement hardware tools, methodologies, and professional services.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Share on Social Networks: